Blood cancer mutations may drive Alzheimer's via inflammatory brain immune cells

A study reported by ScienceDaily describes findings from researchers who identified that somatic mutations linked to blood cancers — the kind that accumulate in haematopoietic stem cells over a lifetime, a phenomenon known as clonal haematopoiesis — may contribute to the development of Alzheimer's disease by generating overly inflammatory microglia or related brain-resident immune cells.

The research adds to a growing body of work exploring how peripheral immune dysfunction influences central nervous system disease. The authors suggest that these mutations cause immune cells to adopt a hyperactivated inflammatory state, which may accelerate the neuroinflammatory processes long associated with Alzheimer's pathology.

The findings carry potential implications for two distinct research directions: first, understanding why older individuals who carry clonal haematopoiesis mutations may face elevated Alzheimer's risk; and second, whether blood-based markers of these mutations could eventually contribute to stratification approaches in Alzheimer's research. The researchers also note that therapeutic agents already in development for blood cancers targeting these mutations could theoretically be explored in neurodegeneration contexts.

The original source is a ScienceDaily summary and the underlying institution, researchers, and journal have not been specified in the available lede. The full primary publication should be consulted before drawing firm conclusions. This is an early-stage research finding and does not represent a change in clinical guidance for either blood cancer or Alzheimer's disease.